Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Ursodeoxycholic Acid, Urso, UDCA
Gallstone Dissolution Agent; hydrophobic bile acid reducer
Original Date: 
May 2022
  • Treatment of Cholestasis
  • PO
  • Ideally taken with food
  • Cholestasis treatment: 10-30 mg/kg/day divided BID-TID. 
  • Cholestasis prevention (from long term TPN): limited data,  20-25 mg/kg/day divided BID-QID has been used.
Side Effects: 
  • GI: diarrhea/constipation, vomiting, nausea
  • Rare: increased LFTs, leukopenia, thrombocytopenia, skin reactions
Parameters to Monitor: 
  • bilirubin, LFTs, CBC
  • Lexi-Comp Online Database, accessed May 2022
  • Liu SY, Chang LW, Wang J, Xie M, Chen LL, Liu W. Ursodeoxycholic acid prevention on cholestasis associated with total parenteral nutrition in preterm infants: a randomized trial. World J Pediatr. 2022 Feb;18(2):100-108.
  • Gokmen T, Oguz SS, Bozdag S, Erdeve O, Uras N, Dilmen U. A controlled trial of erythromycin and UDCA in premature infants during parenteral nutrition in minimizing feeding intolerance and liver function abnormalities. J Perinatol. 2012;32(2):123-128.
  • Arslanoglu S, Moro GE, Tauschel HD, Boehm G. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. J Pediatr Gastroenterol Nutr. 2008;46(2):228-231.
  • British National Formulary for Children- 2018/19 edition. 

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.